

WEST Search History

DATE: Wednesday, January 22, 2003

Set Name Query
side by side

Hit Count Set Name
result set

DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ

L11	l9 and (pulse release)	1	L11
L10	ducassou.inv.	11	L10
L9	lewis.inv.	12699	L9
L8	ducassou.inv	0	L8
L7	L6 and (pulse release)	5	L7
L6	andre.inv.	19070	L6
L5	alaux.inv.	14	L5
L4	L3 and hypnotic	55	L4
L3	L2 and capsule	343	L3
L2	L1 and (tablet or bilayer tablet or bi-layer tablet or minitab mini-tablet or multilayer tablet or multi-layer tablet)	468	L2
L1	(pulse same release)	16319	L1

END OF SEARCH HISTORY

WEST☐ Generate Collection

L23: Entry 71 of 71

File: DWPI

Oct 8, 1998

DERWENT-ACC-NO: 1998-522303

DERWENT-WEEK: 200242

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Solid oral controlled release dosage form preparation - by combining three or four compressed tablets with different, pre-designed release properties, e.g. in pulsed release capsule

INVENTOR: DITTGEN, M; EICHARDT, A ; FRICKE, S ; GERECKE, H ; TIMPE, C ; DITTGEN, M H

PATENT-ASSIGNEE:

ASSIGNEE

CODE

JENAPHARM GMBH & CO KG

JENP

PRIORITY-DATA: 1997DE-1018012 (April 29, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 19718012 C1	October 8, 1998		013	A61K009/52
JP 2002511849 W	April 16, 2002		026	A61K009/48
WO 9848782 A1	November 5, 1998	G	000	A61K009/48
AU 9880099 A	November 24, 1998		000	A61K009/48
EP 979069 A1	February 16, 2000	G	000	A61K009/48
CZ 9903804 A3	April 12, 2000		000	A61K009/22
BR 9809328 A	July 4, 2000		000	A61K009/48
US 6117450 A	September 12, 2000		000	A61K009/22
SK 9901479 A3	July 11, 2000		000	A61K009/48
HU 200003121 A2	February 28, 2001		000	A61K009/52
MX 9909337 A1	November 1, 2000		000	A61K009/48

DESIGNATED-STATES: AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH HU ID IL IS JP KE
KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM
TR TT UA UG UZ VN YU ZW AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC
MW NL OA PT SD SE SZ UG ZW AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
DE 19718012C1	April 29, 1997	1997DE-1018012	
JP2002511849W	April 7, 1998	1998JP-0546469	
JP2002511849W	April 7, 1998	1998WO-DE00979	
JP2002511849W		WO 9848782	Based on
WO 9848782A1	April 7, 1998	1998WO-DE00979	
AU 9880099A	April 7, 1998	1998AU-0080099	
AU 9880099A		WO 9848782	Based on
EP 979069A1	April 7, 1998	1998EP-0928152	
EP 979069A1	April 7, 1998	1998WO-DE00979	
EP 979069A1		WO 9848782	Based on
CZ 9903804A3	April 7, 1998	1998WO-DE00979	
CZ 9903804A3	April 7, 1998	1999CZ-0003804	
CZ 9903804A3		WO 9848782	Based on
BR 9809328A	April 7, 1998	1998BR-0009328	
BR 9809328A	April 7, 1998	1998WO-DE00979	
BR 9809328A		WO 9848782	Based on
US 6117450A	April 24, 1998	1998US-0065863	
SK 9901479A3	April 7, 1998	1998WO-DE00979	
SK 9901479A3	April 7, 1998	1999SK-0001479	
HU 200003121A2	April 7, 1998	1998WO-DE00979	
HU 200003121A2	April 7, 1998	2000HU-0003121	
HU 200003121A2		WO 9848782	Based on
MX 9909337A1	October 12, 1999	1999MX-0009337	

INT-CL (IPC): A61 K 9/22; A61 K 9/26; A61 K 9/28; A61 K 9/48; A61 K 9/52; A61 K 9/56; A61 K 31/56; A61 K 47/30

ABSTRACTED-PUB-NO: DE 19718012C
BASIC-ABSTRACT:

Preparation of an orally administered solid dosage form (specifically a capsule) for controlled release of active agent (I) involves combining at least three out of four compressed tablets (A)-(D) (variable in nature and number) containing at least one (I) (obtained by mixing with additives and/or carriers, granulating, tableting and coating), to provide the desired (I) release profile, e.g. retarded, constant level or special 'rhythm' (pulsed) release. Tablet (A) releases at least 75% of its (I) content within 45 mins. Tablet (B) releases 100% of its (I) content at the earliest after 3 hrs., with a zero-order release profile obtained using a hydrophilic-lipophilic matrix tablets or diffusion-controlled lacquer coating. Tablet (C) releases at least 75% of its (I) content within 45 mins. at pH 6-7.5, and is an analogue of (A) with a gastric juice resistant coating. Tablet (D) releases 100% of its (I) content at the earliest after 3 hrs. at pH 6-7.5, with a zero-order release profile obtained using gastric juice-resistant matrix tablets or combinations of gastric juice-resistant and diffusion controlled lacquer coatings.

USE - The dosage forms are especially useful for administration of: natural body hormones which have a short in vivo half-life (e.g. progesterone, testosterone, dehydro-epiandrosterone, oestriol or oestradiol) or which have levels following a circadian rhythm (e.g. prednisone, prednisolone, cortexone, corticosterone, aldosterone or melatonin); analogues or inhibitors of such hormones, e.g. antidiabetics, glucocorticoids, mineralocorticoids or antihistamines; or combinations of the above drugs.

ADVANTAGE - Solid dosage forms with a variety of controlled release profiles (including pulsed release) can be prepared using a minimum of apparatus and time. By varying the nature and number of components (A)-(D) twelve possible release profile

possibilities are provided.

ABSTRACTED-PUB-NO:

US 6117450A

EQUIVALENT-ABSTRACTS:

Preparation of an orally administered solid dosage form (specifically a capsule) for controlled release of active agent (I) involves combining at least three out of four compressed tablets (A)-(D) (variable in nature and number) containing at least one (I) (obtained by mixing with additives and/or carriers, granulating, tableting and coating), to provide the desired (I) release profile, e.g. retarded, constant level or special 'rhythm' (pulsed) release. Tablet (A) releases at least 75% of its (I) content within 45 mins. Tablet (B) releases 100% of its (I) content at the earliest after 3 hrs., with a zero-order release profile obtained using a hydrophilic-lipophilic matrix tablets or diffusion-controlled lacquer coating. Tablet (C) releases at least 75% of its (I) content within 45 mins. at pH 6-7.5, and is an analogue of (A) with a gastric juice resistant coating. Tablet (D) releases 100% of its (I) content at the earliest after 3 hrs. at pH 6-7.5, with a zero-order release profile obtained using gastric juice-resistant matrix tablets or combinations of gastric juice-resistant and diffusion controlled lacquer coatings.

USE - The dosage forms are especially useful for administration of: natural body hormones which have a short in vivo half-life (e.g. progesterone, testosterone, dehydro-epiandrosterone, oestriol or oestradiol) or which have levels following a circadian rhythm (e.g. prednisone, prednisolone, cortexone, corticosterone, aldosterone or melatonin); analogues or inhibitors of such hormones, e.g. antidiabetics, glucocorticoids, mineralocorticoids or antihistamines; or combinations of the above drugs.

ADVANTAGE - Solid dosage forms with a variety of controlled release profiles (including pulsed release) can be prepared using a minimum of apparatus and time. By varying the nature and number of components (A)-(D) twelve possible release profile possibilities are provided.

CHOSEN-DRAWING: Dwg.0/4

TITLE-TERMS: SOLID ORAL CONTROL RELEASE DOSE FORM PREPARATION COMBINATION THREE FOUR COMPRESS TABLET PRE DESIGN RELEASE PROPERTIES PULSE RELEASE CAPSULE

DERWENT-CLASS: B07

CPI-CODES: B01-A02; B01-B01; B01-B02; B01-C04; B01-C05; B12-M10; B12-M11;

CHEMICAL-CODES:

Chemical Indexing M2 *01*

Fragmentation Code

A212 A960 C710 J0 J011 J1 J171 M225 M231 M262
M281 M320 M411 M431 M510 M520 M530 M540 M620 M630
M782 M903 M904 M910 P432 P816 R052

Specific Compounds

01376K 01376M 01376T

Registry Numbers

1376U

Chemical Indexing M2 *02*

Fragmentation Code

D011 D022 D601 H5 H541 H8 J0 J011 J3 J371
M210 M211 M262 M272 M281 M312 M321 M332 M342 M373
M391 M412 M431 M511 M520 M530 M540 M782 M903 M904
M910 P432 P816 R052

Specific Compounds

00320K 00320M 00320T

Registry Numbers

0320U

Chemical Indexing M5 *03*

Fragmentation Code

M431 M782 M903 M904 P432 P816 R052 S001 S003 S005
S030 S033 S050 S132 S133 S134 S142 S143 S217 S503
S517 U500 U501

Specific Compounds

06173M

Chemical Indexing M5 *04*

Fragmentation Code

M431 M782 M903 M904 M910 P432 P816 R052 S001 S004
S030 S132 S133 S134 S142 S217 S311 S317 S511 S517
S521 S603 S620 U520

Specific Compounds

00012M

Registry Numbers

0012U

Chemical Indexing M5 *05*

Fragmentation Code

M431 M782 M903 M904 M910 P432 P816 R052 S001 S004
S030 S132 S133 S134 S142 S217 S317 S517 S521 S603
S611 S620 U520

Specific Compounds

00067M

Registry Numbers

0067U

Chemical Indexing M5 *06*

Fragmentation Code

M431 M782 M903 M904 M910 P432 P816 R052 S004 S132
S133 S134 S142 S143 S317 S603 S620 U520 U521

Specific Compounds

00145M

Registry Numbers

0145U

Chemical Indexing M1 *07*

Fragmentation Code

F011 F012 F423 H2 H211 H7 H713 H721 J5 J521
L9 L941 M210 M212 M273 M281 M320 M413 M423 M431
M510 M521 M530 M540 M782 M903 M904 P432 P816 R052
V743

Specific Compounds

00546M 00546Q

Registry Numbers

0546S 0546U

Chemical Indexing M1 *08*

Fragmentation Code

H4 H401 H481 H5 H521 H8 M210 M211 M272 M281
M313 M321 M331 M332 M342 M383 M391 M423 M431 M782
M903 M904 P432 P816 R052 V713

Specific Compounds

06563M

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0012U; 0067U ; 0145U ; 0320U ; 0546S ; 0546U ;
1376U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1998-156950